Press
Releases

Providence Therapeutics Announces Donna T. Ward, Ph.D., J.D. appointment to Board of Directors

Written on Thursday, 28 October 2021

Northern RNA and Providence Therapeutics Announce Multi-year Agreement to Provide Essential Raw Materials and GMP Manufacturing in Support of Providence Therapeutics mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B

Northern RNA and Providence Therapeutics Announce Multi-year Agreement to Provide Essential Raw Materials and GMP Manufacturing in Support of Providence Therapeutics mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B

Written on Tuesday, 14 September 2021

Emergent Biosolutions Secures Multi-year Development and Manufacturing Agreement With Providence Therapeutics for Its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B

Emergent Biosolutions Secures Multi-year Development and Manufacturing Agreement With Providence Therapeutics for Its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B

Written on Tuesday, 14 September 2021

Providence Therapeutics Enters into Comprehensive Agreements with Everest Medicines to Advance mRNA Vaccines and Therapies, including COVID-19 Vaccines, in Emerging Markets in Asia

Providence Therapeutics Enters into Comprehensive Agreements with Everest Medicines to Advance mRNA Vaccines and Therapies, including COVID-19 Vaccines, in Emerging Markets in Asia

Written on Monday, 13 September 2021

Providence Therapeutics Reports PTX-COVID19-B, its mRNA Vaccine for COVID-19, Neutralizes SARS-CoV-2 and Variants of Concern, Including Delta

Providence Therapeutics Reports PTX-COVID19-B, its mRNA Vaccine for COVID-19, Neutralizes SARS-CoV-2 and Variants of Concern, Including Delta

Written on Monday, 13 September 2021

Providence Therapeutics Holdings Inc. Of Canada and Biological E. Limited of India Announce the Execution of a Term Sheet for the Licensing and Collaboration of mRNA Vaccine

Providence Therapeutics Holdings Inc. Of Canada and Biological E. Limited of India Announce the Execution of a Term Sheet for the Licensing and Collaboration of mRNA Vaccine

Written on Tuesday, 01 June 2021

Providence Therapeutics Announces Very Favorable Interim Phase 1 Trial Data for PTX-COVID19-B, its mRNA Vaccine Against COVID-19

Written on Wednesday, 12 May 2021

Providence Therapeutics Announces First Subject Has Been Dosed in Covid-19 Vaccine Trial

Providence Therapeutics Announces First Subject Has Been Dosed in Covid-19 Vaccine Trial

Written on Tuesday, 26 January 2021

Providence Therapeutics Announces New Chief Development Officer and Chief Medical Officer

Providence Therapeutics Announces New Chief Development Officer and Chief Medical Officer

Written on Friday, 22 January 2021

Providence Therapeutics COVID-19 Vaccine Receives Health Canada Authorization to Begin Clinical Trials

Providence Therapeutics COVID-19 Vaccine Receives Health Canada Authorization to Begin Clinical Trials

Written on Wednesday, 23 December 2020

Providence Therapeutics Submits Clinical Trial Application (CTA) to Health Canada for its mRNA COVID Vaccine

Providence Therapeutics Submits Clinical Trial Application (CTA) to Health Canada for its mRNA COVID Vaccine

Written on Friday, 04 December 2020

Providence Therapeutics Announces Jared Davis as President

Providence Therapeutics Announces Jared Davis as President

Written on Tuesday, 01 December 2020

Providence Therapeutics Reports Supportive Preclinical Data for its COVID-19 Vaccine Candidate (PTX-COVID19-B)

Providence Therapeutics Reports Supportive Preclinical Data for its COVID-19 Vaccine Candidate (PTX-COVID19-B)

Written on Wednesday, 05 August 2020